GPR3 And GPR6, Novel Molecular Targets For Cannabidiol

Alzheimer's Disease Parkinson's Disease

Key Findings

Study results demonstrate for the first time that both GPR3 and GPR6 are novel molecular targets for CBD. Our discovery that CBD acts as a novel inverse agonist on both GPR3 and GPR6 indicates that some of the potential therapeutic effects of CBD (e.g. treatment of Alzheimer's disease and Parkinson's disease) may be mediated through these important receptors.

Information and Links


Link: GPR3 And GPR6, Novel Molecular Targets For Cannabidiol

Year: 2017

DOI: https://doi.org/10.1016/j.bbrc.2017.05.165


Ratings

(How Ratings Work)

Alzheimer's Disease — 1


Possibility of efficacy for cannabis in treatment of Alzheimer's Disease according to the results found in this study.

Parkinson's Disease — 1


Possibility of efficacy for cannabis in treatment of Parkinson's Disease according to the results found in this study.

Drugs Used

CBD